Table 3

Studies of topical doxepin

StudyYearSetting/designInclusion criteriaPatient numberInterventionControlOutcomesFollow-up
Kwa et al332020Multicenter cross-over RCTHealed burn, itch VAS≥3, pruritic area <10%27Doxepin creamPlacebo creamPruritus VAS
BIQ at week 2 and week 5		5 weeks
Kwa et al322019Multicenter RCTHealed burn, itch VAS≥331Doxepin cream and placebo tabletPlacebo cream and antihistamine tabletPruritus VAS
BIQ
QOL SF-36
Somnolence
Erythema		12 weeks
Demling et al342003Single center RCTHealed, <35% TBSA partial thickness burn, pruritic area <20%31DoxepinStandard carePruritus VAS
Erythema (Vancouver Scar Scale)		12 weeks
Demling et al312002Single center RCTHealed burn, pruritic area <15%41DoxepinStandard carePruritus VAS
Erythema (Vancouver Scar Scale)		12 weeks

  • BIQ, Burn Itch Questionnaire; QOL SF-36, Quality of Life Short Form-36 questionnaire; VAS, Visual Analog Scale.